The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Subscribe To Our Newsletter & Stay Updated
